I'll research ELV before writing the preview. Let me start by gathering recent earnings materials, filings, and news.Let me read the most recent Q1 2026 earnings materials and get broader news context.Let me pull the Q1 2026 earnings release for exact figures, recent stock price action, and analyst context via web search.Let me get recent news context and analyst expectations via web search.I now have what I need. Here's the earnings preview.
Elevance heads into Q2 as a "recovery/reset" story that the market has already begun to reward. After a brutal 2025 and a January 2026 selloff, the stock has staged a powerful rebound — closing at ~$427 on July 14, up ~20% YTD and roughly +50% off its early-March trough (~$284). The rally has been sector-wide (favorable final 2027 MA rates in April lifted the whole group), but it means expectations into the print are no longer depressed. The key tension: management set a deliberately conservative, "prudent and achievable" bar for 2026, yet the shares now price in a credible earnings recovery. Q2 is the quarter to test whether the improving-trend narrative from Q1 is real — and it lands two weeks before a hard July 31 CMS compliance deadline that could be the bigger swing factor than the numbers themselves.
Because Q2 is a seasonally lighter quarter and the number is largely pre-telegraphed, the guidance update and the CMS commentary will matter far more than the headline EPS.
Q1 was a beat: adjusted EPS of $12.58, of which ~$0.45 was core outperformance and ~$1.00 was non-recurring investment income. Management raised FY26 adjusted EPS to "at least $26.75" (from ~$25.50), but explicitly told investors to strip the ~$1 nonrecurring item — so the 2027 growth baseline is $25.75, off which they promised "at least 12% adjusted EPS growth." Given the front-loaded Q1 and conservative framing, watch whether they nudge the guide higher again or hold the line. A reaffirmation with confident trend language is the likely "good" outcome; a raise would be a positive surprise; any hedging on trend would sting given the re-rated stock.
This is the elephant in the room. In Q1, ELV took a $935M accrual as its best estimate of exposure for historical Medicare Advantage risk-adjustment data (per a Feb 27, 2026 CMS notice). Management stressed it does not reflect current practices and expects that if it completes CMS's prescribed steps by the July 31 deadline, the sanctions will not take effect. Because earnings fall just before that deadline, expect pointed questions on: (a) progress toward resolution, (b) whether the $935M estimate holds, and (c) any cash payment timing (FY26 OCF guide of ≥$5.5B is stated to be inclusive of potential CMS payments). Clarity here could be a bigger de-risking event than the quarter itself.
Consolidated BER was 86.8% in Q1 (+40 bps YoY), with Medicaid the pressure point and Medicare running better than expected. Management said ~2/3 of Q1 outperformance was genuine claims favorability (helped by a milder flu season worth ~$0.10) and credited its own actions — utilization management, payment integrity, and site-of-care optimization. Watch for: confirmation that trend is still "tracking in line," and whether the self-help levers are compounding. They were adamant they are not banking on a better trend environment — so the Q2 MLR is the reality check.
The most important structural debate. Management reiterated 2026 is the trough year for Medicaid margins, guiding to ~‑1.75% operating margin for the year, with rates coming in at the mid-single-digit range — still below the trend, leaving a rate-to-trend gap they're working to close with states. Key watch items: - July rate updates (Felicia Norwood flagged these were just beginning at Q1) — the first real read on 2H rate adequacy. - Membership: guided to a high-single-digit decline; expected to finish near the better end. But better retention risks pushing acuity pressure into 2027. - Any language on state exits if paths to profitability don't materialize.
This is where enrollment strength could be a red flag rather than a positive. Enhanced premium subsidies expired at end-2025, and ELV priced 2026 prudently. Q1 showed a pronounced shift toward bronze plans (which defer costs to 2H) and effectuation tracking to ~1.2M members at Q2-end vs. an initial full-year outlook of ≥900K. Watch for: - Whether they revise the full-year membership outlook upward (they held off in Q1). - Any read on risk-pool morbidity — management said renewing/paying members show higher prior claims than lapsed cohorts, consistent with pricing so far. Given bronze benefit designs defer claims into 2H, the back half is when ACA margin risk shows up — so tone here matters.
| Bull case | Bear case | |
|---|---|---|
| Trend | Self-help + milder utilization keep BER in check; another beat | Medicaid trend re-accelerates; rate gap persists |
| CMS | Clean July-31 resolution path confirmed; $935M holds | Estimate revised higher; sanction/cash overhang lingers |
| ACA | Bronze mix + prudent pricing = manageable morbidity | 2H claims from bronze deferral + sicker pool pressure margin |
| Guide | Raise or confident reaffirm; 2027 ≥12% intact | Any trend hedging disappoints a re-rated stock |
| Valuation | Still cheap vs. history if $25.75 baseline is real | +50% off lows; priced for execution, little margin for error |
Q2 EPS is largely pre-set (~23% of the $26.75 full-year, ~$6.15). The report will be judged on (1) whether management sustains the "improving trend, prudent guide" story and reaffirms/raises the ≥$26.75 FY26 and ≥12% 2027 growth framework, and (2) any concrete update on the CMS risk-adjustment matter ahead of the July 31 deadline. With the stock near highs after a ~50% rebound, the bar has quietly risen — a clean quarter plus CMS de-risking is what's needed to keep the recovery narrative intact; conservative execution that merely "confirms" may not be enough to satisfy a market that has already moved.
(Watch specifically: consolidated BER, Medicaid operating margin trajectory vs. the ‑1.75% FY target, ACA full-year membership guidance, Carelon segment margins, DCP (was 46.6 days in Q1), and the FY26/2027 EPS framework.)
Sources: ELV Q1 2026 earnings call transcript and earnings release; Finnhub price history; and third-party earnings-preview coverage for consensus estimates. Consensus figures are approximate and vary by data provider.